LAUSR

With the widespread use of monoclonal antibodies directed against cytokines in the treatment of psoriasis, we are presented with opportunities to investigate paradigms in cutaneous immunology, notably with respect to the ongoing skin inflammation that ‘escapes’ these therapies. Ustekinumab, a monoclonal antibody targeting the shared p40 subunit of IL-12 and IL-23, is a frequently used systemic treatment for psoriasis, blocking both Th1 and Th17 responses. Interestingly, most ‘responders’ to biologics, still have areas of persistent disease involvement, often presenting with moderate-to-severe psoriatic plaques, localized to one or a few locations on the body while under treatment. This article is protected by copyright. All rights reserved.